(0.09%) 5 308.13 points
(-0.49%) 39 807 points
(0.65%) 16 795 points
(-0.64%) $79.29
(-0.51%) $2.74
(-0.83%) $2 418.20
(-2.62%) $31.58
(-1.79%) $1 044.70
(0.06%) $0.921
(0.23%) $10.72
(0.01%) $0.787
(0.03%) $90.71
Live Chart Being Loaded With Signals
Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and the People's Republic of China...
Stats | |
---|---|
Šios dienos apimtis | 24 323.00 |
Vidutinė apimtis | 190 072 |
Rinkos kapitalizacija | 3.42M |
EPS | $0 ( 2024-04-02 ) |
Kita pelno data | ( $0 ) 2024-08-12 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.190 |
ATR14 | $0.00900 (2.92%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2021-11-01 | Tauzin W J | Buy | 8 000 | Stock Option (right to buy) |
2021-05-01 | Tauzin W J | Buy | 8 000 | Stock Option (right to buy) |
2022-05-01 | Tauzin W J | Buy | 8 000 | Stock Option right to buy) |
2022-11-01 | Tauzin W J | Buy | 8 000 | Stock Option (right to buy) |
2022-01-01 | Tauzin W J | Buy | 4 000 | Stock Option (right to buy) |
INSIDER POWER |
---|
99.83 |
Last 100 transactions |
Buy: 44 704 561 | Sell: 8 187 803 |
Tūris Koreliacija
Avalon GloboCare Corp. Koreliacija
10 Labiausiai teigiamai susiję koreliacijos |
---|
10 Labiausiai neigiamai susiję koreliacijos |
---|
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Avalon GloboCare Corp. Koreliacija - Valiuta/Žaliavos
Avalon GloboCare Corp. Finansinės ataskaitos
Annual | 2023 |
Pajamos: | $1.26M |
Bruto pelnas: | $202 789 (16.15 %) |
EPS: | $-1.590 |
FY | 2023 |
Pajamos: | $1.26M |
Bruto pelnas: | $202 789 (16.15 %) |
EPS: | $-1.590 |
FY | 2022 |
Pajamos: | $1.20M |
Bruto pelnas: | $272 728 (22.69 %) |
EPS: | $-1.360 |
FY | 2021 |
Pajamos: | $1.39M |
Bruto pelnas: | $414 518 (29.80 %) |
EPS: | $-1.100 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Avalon GloboCare Corp.
Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and the People's Republic of China. The company offers medical related consulting services, including research studies, executive education, daily online executive briefings, tailored expert advisory services, and consulting and management services in the areas of immunotherapy and second opinion/referral services. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia; and AVA-011 that has completed pre-clinical laboratory studies and undergoing IND-enabling process development stage to generate cGMP-grade AVA-011 CAR-T cells. It is also developing RNA-based FASH-CARTM cell therapy platform. In addition, the company develops avalon clinical-grade tissue-specific exosome (ACTEX); offers therapeutic and diagnostic targets utilizing QTY-code protein design technology with Massachusetts Institute of Technology (MIT), including using the QTY code protein design technology for development of a hemofiltration device to treat Cytokine Storm; and provides co-development of next generation, transposon-based, multi-target CAR-T, CAR-NK, and other immune effector cell therapeutic modalities with Arbele Limited. Further, it has strategic partnership with the University of Natural Resources and Life Sciences in Vienna and Austria to develop an S-layer vaccine that could be administered by an intranasal or oral route against SARS-CoV-2 and coronavirus that causes COVID-19 disease; and develops Avalon Cell and Avalon Rehab, as well as promotes standardization related to exosome industry. The company is headquartered in Freehold, New Jersey.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.